Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOXCEL THERAPEUTICS, INC.

(BTAI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BioXcel Therapeutics : Says Therapeutics Study Shows Anti-Tumor Activity of Prostate Cancer Combination Therapy

09/16/2021 | 07:34am EDT


ę MT Newswires 2021
All news about BIOXCEL THERAPEUTICS, INC.
10/25BIOXCEL THERAPEUTICS : Regulation FD Disclosure - Form 8-K
PU
10/25BIOXCEL THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
10/18BIOXCEL THERAPEUTICS : Advances Prostate Cancer Drug Candidate to Efficacy Portion of Mid-..
MT
10/18BIOXCEL THERAPEUTICS : Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Trea..
AQ
10/18BioXcel Therapeutics, Inc. Announces Expansion of Phase 2 Trial of BXCL701 in De Novo a..
CI
10/13BIOXCEL THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/13Bioxcel Therapeutics, Inc. Announces Executive Changes
CI
09/23BIOXCEL THERAPEUTICS : to Highlight Novel Approaches in AI-Based Drug Candidate Discovery ..
PU
09/23BIOXCEL THERAPEUTICS : to Highlight Novel Approaches in AI-Based Drug Candidate Discovery ..
AQ
09/16BIOXCEL THERAPEUTICS : Says Therapeutics Study Shows Anti-Tumor Activity of Prostate Cance..
MT
More news
Analyst Recommendations on BIOXCEL THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -118 M - -
Net cash 2021 221 M - -
P/E ratio 2021 -6,77x
Yield 2021 -
Capitalization 836 M 836 M -
EV / Sales 2021 -
EV / Sales 2022 9,74x
Nbr of Employees 50
Free-Float 66,1%
Chart BIOXCEL THERAPEUTICS, INC.
Duration : Period :
BioXcel Therapeutics, Inc. Technical Analysis Chart | BTAI | US09075P1057 | MarketScreener
Technical analysis trends BIOXCEL THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 29,89 $
Average target price 89,80 $
Spread / Average Target 200%
EPS Revisions
Managers and Directors
Vimal D. Mehta President, Chief Executive Officer & Director
Richard I. Steinhart Chief Financial Officer & Vice President
Peter R. Mueller Chairman
Frank D. Yocca Chief Scientific Officer & Senior Vice President
Vincent J. O'Neill Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BIOXCEL THERAPEUTICS, INC.-35.30%836
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992